G3BP1

Ras GTPase-activating protein-binding protein 1 · Q13283 · G3BP1 on Sugi Atlas →

0 patent compounds predicted against G3BP1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to G3BP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 PHASE2COMPLETED
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation PHASE1/PHASE2RECRUITING
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 PHASE2COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer PHASE2COMPLETED
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma PHASE1ACTIVE_NOT_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Gemcitabine and Dasatinib in Advanced Solid Tumors PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Expression and Function of the Renin-Angiotensin System in the Esophagus EARLY_PHASE1COMPLETED
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients nanUNKNOWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN
Long Term Prediction of MASH-related HCC Risk by Proteomics nanNOT_YET_RECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Studying Genes in Samples From Younger Patients With Rhabdomyosarcoma nanCOMPLETED
Solid Tumors in RASopathies nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Circulating Biomarker Signatures for the Detection of Gastric Preneoplasia and Cancer nanRECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a G3BP1 binder may also engage these)

ProteinNameSimilarity
Q32LC7 1.000 Q32LC7 →
Q5RB87 1.000 Q5RB87 →
P97855 1.000 P97855 →
P97379 1.000 P97379 →
G3BP2 Ras GTPase-activating protein-binding protein 2 0.999 landscape →
Q5R9L3 0.998 Q5R9L3 →
Q0VFL7 0.963 Q0VFL7 →
YTHDF1 YTH domain-containing family protein 1 0.958 landscape →
EIF4B Eukaryotic translation initiation factor 4B 0.955 landscape →
YTHDF3 YTH domain-containing family protein 3 0.954 landscape →
O77768 0.954 O77768 →
A2VDN6 0.954 A2VDN6 →
G3V9R8 0.953 G3V9R8 →
HNRNPC Heterogeneous nuclear ribonucleoproteins C1/C2 0.953 landscape →
SF3A1 Splicing factor 3A subunit 1 0.952 landscape →
Q5RFL8 0.951 Q5RFL8 →
P19600 0.950 P19600 →
Q8BYK6 0.950 Q8BYK6 →
Q8BGD9 0.949 Q8BGD9 →
Q9Z204 0.949 Q9Z204 →
Q8K4Z5 0.949 Q8K4Z5 →
KHDRBS1 KH domain-containing, RNA-binding, signal transduction-associated protein 1 0.949 landscape →
Q5R5W2 0.949 Q5R5W2 →
Q9UKM9 0.948 Q9UKM9 →
Q9WU01 0.948 Q9WU01 →
P59326 0.948 P59326 →
Q8CGC4 0.947 Q8CGC4 →
Q9P2N5 0.947 Q9P2N5 →
O95628 0.947 O95628 →
Q28F51 0.946 Q28F51 →